Top

Published in:

Open Access 01-12-2022 | Cervical Cancer | Study protocol

Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial

Authors: Jing Li, Hua Liu, Ya Li, Jian Li, Lifei Shen, Wenqing Long, Chenmin Yang, Haoping Xu, Wenqi Xi, Rong Cai, Weiwei Feng

Published in: Trials | Issue 1/2022

Abstract

Background

Currently, the standard treatment for locally advanced cervical cancer is concurrent chemoradiation (CCRT). The effect of neoadjuvant chemotherapy in advanced cervical cancer is controversial. Studies have shown that the addition of a weekly regimen of neoadjuvant chemotherapy (NACT) followed by CCRT may be superior to a thrice-weekly regimen of NACT and CCRT. Among patients who had not received prior cisplatin, a cisplatin and paclitaxel (TP) regimen resulted in longer overall survival than other regimens. This study aims to investigate the feasibility, safety, and efficacy of NACT with weekly TP followed by CCRT.

Methods

This is a prospective, randomized, open-labeled, multicentered phase III study. Based on a 65% of 2-year disease-free survival (DFS) rate in the CCRT group and 80% of that in NACT followed by CCRT group, and on prerequisite conditions including an 8% loss to follow-up, a two-sided 5% of type I error probability, and an 80% of power, a total of 300 cases were required for enrollment. Patients with IIB–IVA cervical cancer will be randomly allocated in a 1:1 ratio to one of two intervention arms. In the study arm, patients will receive dose-dense cisplatin (40 mg/m²) and paclitaxel (60 mg/m²) weekly for 4 cycles followed by CCRT (45 Gy in 5 weeks concurrent with cisplatin 40 mg/m² weekly) plus image-guided adaptive brachytherapy (IGBRT). In the control arm, patients will undergo CCRT treatment. The primary endpoint of the study is 2-year disease-free survival (DFS); the secondary endpoints are 5-year overall survival (OS) and disease-free survival (DFS), the response rate 3 months after treatment completion, grade III/IV adverse effects, and quality of life, and potential biomarkers for predicting treatment response will also be studied.

Discussion

The data gathered from the study will be used to determine whether NACT with weekly TP followed by CCRT may become an optimized treatment for locally advanced cervical cancer.

Trial registration

Chinese Clinical Trial Registry ChiCTR1900025327. Registered on 24 August 2019. medresman.org.cn ChiCTR1900025326

Small W, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–12. https://doi.org/10.1002/cncr.30667.CrossRef

Tharavichitkul E, Lorvidhaya V, Kamnerdsupaphon P, Sukthomya V, Chakrabandhu S, Klunklin P, et al. Combined chemoradiation of cisplatin versus carboplatin in cervical carcinoma: a single institution experience from Thailand. BMC Cancer. 2016;16(1):501. https://doi.org/10.1186/s12885-016-2558-9.CrossRefPubMedPubMedCentral

Frei E 3rd. Clinical cancer research: an embattled species. Cancer. 1982;50(10):1979–92. https://doi.org/10.1002/1097-0142(19821115)50:10<1979::AID-CNCR2820501002>3.0.CO;2-D.CrossRefPubMed

Zhu Y, Yang J, Zhang X, et al. Acquired treatment response from neoadjuvant chemotherapy predicts a favorable prognosis for local advanced cervical cancer: a meta-analysis. Medicine (Baltimore). 2018;97:e0530.CrossRef

Chantalat E, Vidal F, Leguevaque P, Lepage B, Mathevet P, Deslandres M, et al. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers. Eur J Obstet Gynecol Reprod Biol. 2015;193:118–22. https://doi.org/10.1016/j.ejogrb.2015.07.017.CrossRefPubMed

Yuko S, Yutaka N, Takafumi T, et al. A phase II study of neoadjuvant chemotherapy followed by extended field concurrent chemoradiotherapy for para-aortic lymph node positive cervical cancer. Anticancer Res. 2020;40(6):3565–70. https://doi.org/10.21873/anticanres.14346.CrossRef

de Azevedo CRAS, Thuler LCS, de MMJG, et al. Neoadjuvant chemotherapy followed by chemoradiation in cervical carcinoma: a review. Int J Gynecol Cancer. 2016;26(4):729–36. https://doi.org/10.1097/IGC.0000000000000663.CrossRefPubMed

Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39(17):2470–86. https://doi.org/10.1016/S0959-8049(03)00425-8.CrossRef

Narayan S, Sharma N, Kapoor A, Sharma R, Kumar N, Singhal M, et al. Pros and cons of adding of neoadjuvant chemotherapy to standard concurrent chemoradiotherapy in cervical cancer: a regional cancer center experience. J Obstet Gynaecol India. 2016;66(5):385–90. https://doi.org/10.1007/s13224-015-0698-5.CrossRefPubMed

10.

da Costa Samantha Cabral S, Colombo BR, Gabrielli Flavia Carolina G, et al. Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer: a randomized phase II trial. J Clin Oncol. 2019;37:3124–31.CrossRef

11.

Singh RB, Chander S, Mohanti BK, Pathy S, Kumar S, Bhatla N, et al. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study. Gynecol Oncol. 2013;129(1):124–8. https://doi.org/10.1016/j.ygyno.2013.01.011.CrossRefPubMed

12.

McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs MA, Symonds RP, Warwick V, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013;108(12):2464–5. https://doi.org/10.1038/bjc.2013.230.CrossRefPubMedPubMedCentral

13.

Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015;33(19):2129–35. https://doi.org/10.1200/JCO.2014.58.4391.CrossRefPubMed

14.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef

15.

Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802–12. https://doi.org/10.1200/JCO.2008.16.4368.CrossRefPubMedCentral

16.

Marita A, Ordeanu C, Rancea A, Nicolae T, Nagy VM. Long-term survival following neoadjuvant chemotherapy and concomitant radiochemotherapy in locally advanced cervical cancer: results of the Oncology Institute “Prof. Dr. Ion Chiricuta” experience. J Med Life. 2018;11(1):42–50.PubMedPubMedCentral

17.

Koshiba H, Hosokawa K, Mori T, et al. Intravenous paclitaxel is specifically retained in human gynecologic carcinoma tissues in vivo. Int J Gynecol Cancer. 2009;19(4):484–8.CrossRef

18.

de Azevedo CRAS, Thuler LCS, de Mello MJG, de Oliveira Lima JT, da Fonte ALF, Fontão DFS, et al. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecol Oncol. 2017;146(3):560–5. https://doi.org/10.1016/j.ygyno.2017.07.006.CrossRefPubMed

19.

Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649–55. https://doi.org/10.1200/JCO.2009.21.8909.CrossRefPubMedPubMedCentral

Title: Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial
Authors: Jing Li
Hua Liu
Ya Li
Jian Li
Lifei Shen
Wenqing Long
Chenmin Yang
Haoping Xu
Wenqi Xi
Rong Cai
Weiwei Feng
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Cervical Cancer
Cervical Cancer
Cytostatic Therapy
Published in: Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-021-05986-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial

Abstract

Background

Methods

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

Efficacy of a new membrane obturator prosthesis in terms of speech, swallowing, and the quality of life of patients with acquired soft palate defects: study protocol of the VELOMEMBRANE randomized crossover trial

Traditional acupuncture and laser acupuncture in chronic nonspecific neck pain: study protocol for a randomized controlled trial

Electrical dry needling versus conventional physiotherapy in the treatment of active and latent myofascial trigger points in patients with nonspecific chronic low back pain

EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil

CeRebrUm and CardIac Protection with ALlopurinol in Neonates with Critical Congenital Heart Disease Requiring Cardiac Surgery with Cardiopulmonary Bypass (CRUCIAL): study protocol of a phase III, randomized, quadruple-blinded, placebo-controlled, Dutch multicenter trial

PAciFy Cough—a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough